No psychedelic is rescheduled out of Schedule I in 2026 absent full FDA approval.

Right now, psychedelics like psilocybin and MDMA sit in the most restricted drug category the US has. The DEA (the agency that enforces drug laws) only moves a drug to a less restricted category after the FDA (the US drug regulator) fully approves it as medicine. Since no psychedelic has full FDA approval yet, nothing changes in 2026.

Scheduling follows approval, not advocacy. No FDA action today means no DEA movement. Our diversion mandate stays intact until then.